Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Dynamk Capital is a New York-based venture capital firm founded in 2016. The firm focuses exclusively on Life Science Industrials, which encompass the tools, technologies, and services that facilitate the discovery, development, and manufacturing of biotherapeutics. Dynamk Capital was established to support entrepreneurs and innovators in the life sciences sector, particularly those providing fundamental technologies and services to the biopharmaceutical industry.
As of 2021, Dynamk Capital has a total AUM of $65 million, with a portfolio comprising 13 companies. The firm collaborates with family offices, high net worth individuals, and strategic partners from the biopharma and life sciences sectors, including notable names like Pfizer Inc. through Pfizer Ventures, JSR Group, and Lonza AG. The firm is headquartered at 30 Wall Street, 12th Floor, New York, NY 10005.
Dynamk Capital invests in the life sciences sector, specifically targeting startups that provide technologies and services to the biopharma industry. Their investment thesis emphasizes biotechnology, cell and gene therapies, vaccines, and regenerative medicine. The firm seeks to invest in disruptive technologies that enable the full biopharma continuum, including drug discovery, clinical development, and manufacturing of biotherapeutics.
Investment stages range from Seed through Series A, B, and growth. Dynamk Capital looks for startups that are innovating within the life sciences, particularly those that can demonstrate a clear path to commercialization. The firm values partnerships with entrepreneurs who are committed to advancing the biopharmaceutical landscape and are equipped with the necessary expertise to drive their innovations forward.
Dynamk Capital's portfolio includes a diverse range of companies that are making significant strides in the life sciences sector. Notable companies include:
Daniella Kranjac — Founding Partner. Daniella has a background in venture capital and life sciences, having led investments in various biotech companies. She is known for her expertise in identifying disruptive technologies within the life sciences sector.
To pitch Dynamk Capital, founders should visit their website at dynamk.vc. It is recommended to include a comprehensive deck that outlines the business model, market opportunity, and technology details. While specific response times are not mentioned, founders should expect a thorough review process.
Warm introductions are preferred, as they can facilitate a more favorable reception of the pitch.
As of 2021, Dynamk Capital completed the final close of its fund, Dynamk Life Sciences Fund L.P., with a total AUM of $65 million. The firm has been actively building its portfolio, which includes 13 companies focused on life science industrials.
Recent portfolio highlights include investments in companies like bit.bio and Alpenglow Biosciences, which are making significant advancements in human cell manufacturing and 3D tissue imaging, respectively.
What are Dynamk Capital's investment criteria?
Dynamk Capital focuses on life sciences startups that provide essential technologies and services to the biopharmaceutical industry. They look for companies innovating in biotechnology, cell and gene therapies, vaccines, and regenerative medicine.
How can I apply or pitch to Dynamk Capital?
Founders can pitch to Dynamk Capital through their website at dynamk.vc. It is advisable to include a detailed business plan and information about the technology or service being offered.
What makes Dynamk Capital different from other VC firms?
Dynamk Capital specializes in Life Science Industrials, focusing on the enabling technologies for biopharmaceuticals rather than just drug assets. This unique focus allows them to support a critical segment of the life sciences ecosystem.
What is the geographic scope of Dynamk Capital's investments?
The firm primarily invests in North America, specifically the United States, targeting startups that are positioned to make significant impacts in the life sciences sector.
What is the typical check size for investments?
Dynamk Capital invests across various stages, including Seed through Series A, B, and growth, although specific check sizes are not disclosed.
What kind of post-investment involvement does Dynamk Capital have?
The firm provides hands-on commercialization and exit support through a team of entrepreneurs and industry executives, enhancing the growth and success of its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.